Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab vs EXTREME in First-Line R/M SCCHN
NCT02741570Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall Survival in Participants With PD-L1 CPS >= 20 up to 55 months and Overall Survival in All Randomized Participants up to 55 months. Started Oct 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02741570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02741570.